Trials / Completed
CompletedNCT02300233
The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 114 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in participants with Hypertriglyceridemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Volanesorsen | 300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks. |
| DRUG | Placebo | Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks. |
Timeline
- Start date
- 2015-02-05
- Primary completion
- 2016-07-27
- Completion
- 2017-01-24
- First posted
- 2014-11-24
- Last updated
- 2022-04-13
- Results posted
- 2022-04-13
Locations
45 sites across 6 countries: United States, Canada, France, Germany, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02300233. Inclusion in this directory is not an endorsement.